Financial Survey: Decision Diagnostics (OTCMKTS:DECN) vs. Precipio (NASDAQ:PRPO)

Decision Diagnostics (OTCMKTS:DECN) and Precipio (NASDAQ:PRPO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility and Risk

Decision Diagnostics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Precipio has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Decision Diagnostics and Precipio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decision Diagnostics	0	0	0	0	0.00
Precipio	1	0	0	0	1.00

Given Decision Diagnostics’ higher probable upside, equities analysts plainly believe Decision Diagnostics is more favorable than Precipio.

Earnings & Valuation

This table compares Decision Diagnostics and Precipio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A
Precipio	$18.53 million	2.28	-$4.29 million	($0.82)	-29.48

Decision Diagnostics has higher earnings, but lower revenue than Precipio.

Insider & Institutional Ownership

10.5% of Precipio shares are held by institutional investors. 16.9% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Decision Diagnostics and Precipio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decision Diagnostics	N/A	N/A	N/A
Precipio	-5.50%	-10.07%	-6.71%

Summary

Precipio beats Decision Diagnostics on 5 of the 9 factors compared between the two stocks.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.

About Precipio

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.